Fresno, CA

Limb Preservation Platform Inc

Foot Ulcer

Ulcer

Diabetic Foot

Vitruvian Medical Devices

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical trial is to determine the safety of DERMASEAL for the treatment of non-healing, neuropathic diabetic foot ulcers. The main outcome measure is safety. A total of twenty-four (24) participants will be randomized to receive up to four (4) consecutive weeks of treatment with either standard of care (SOC), plasma film + SOC, or plasma film containing silver microparticles (DERMASEAL) + SOC, with a final follow-up visit 12 weeks after the last treatment.

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

Limb Preservation Platform Inc | Fresno, CA

Site insights

Work at this site?

Active trials

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

Trial sponsors